The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Open accessAbstract
There is a continuing debate about the proportion of cancer patients that benefit from precision oncology, attributable in part to conflicting views as to which molecular alterations are clinically actionable. To quantify the expansion of clinical actionability since 2017, we annotated 47,271 solid tumors sequenced with the MSK-IMPACT clinical assay using two temporally distinct versions of the OncoKB knowledge base deployed 5 years apart. Between 2017 and 2022, we observed an increase from 8.9% to 31.6% in the fraction of tumors harboring a standard care (level 1 or 2) predictive biomarker of therapy response and an almost halving of tumors carrying nonactionable drivers (44.2% to 22.8%). In tumors with limited or no clinical actionability, TP53 (43.2%), KRAS (19.2%), and CDKN2A (12.2%) were the most frequently altered genes. Significance: Although clear progress has been made in expanding the availability of precision oncology-based treatment paradigms, our results suggest a continued unmet need for innovative therapeutic strategies, particularly for cancers with currently undruggable oncogenic drivers. See related commentary by Horak and Fröhling, p. 18. This article is featured in Selected Articles from This Issue, p. 5
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“Cumulative technical advances have now enabled clinical sequencing panels to detect mutations and structural alterations in hundreds of cancer-associated genes at low cost using readily available archival tumor tissue or tumor-derived cell-free DNA (34–37).”
BackgroundSelf-citationOncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
Self-citationOverall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationOncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,589
Self-citationMarabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., et al. (2017) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.002 · Cited by 2,030
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964
Self-citationSacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Self-citationEnfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data
Niu, B., Ye, K., Zhang, Q., Lu, C., Xie, M., McLellan, M. D., Wendl, M. C., & Ding, L. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt755 · Cited by 832
Self-citationMassard, C., Michiels, S., Ferté, C., Le Deley, M.-C., Lacroix, L., Hollebecque, A., Verlingue, L., Ileana, E., Rosellini, S., Ammari, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1396 · Cited by 783
Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 666
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Griffith, M., Spies, N. C., Krysiak, K., McMichael, J. F., Coffman, A. C., Danos, A. M., Ainscough, B. J., Ramirez, C. A., Rieke, D. T., Kujan, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3774 · Cited by 628
The emerging clinical relevance of genomics in cancer medicine
Berger, M. F., & Mardis, E. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0002-6 · Cited by 626
Self-citationVan Allen, E. M., Wagle, N., Stojanov, P., Perrin, D. L., Cibulskis, K., Marlow, S., Jane-Valbuena, J., Friedrich, D. C., Kryukov, G., Carter, S. L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3559 · Cited by 546
Subbiah, V., Lassen, U., Élez, E., Italiano, A., Curigliano, G., Javle, M., de Braud, F., Prager, G. W., Greil, R., Stein, A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30321-1 · Cited by 533
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations
Tamborero, D., Rubio-Perez, C., Deu-Pons, J., Schroeder, M. P., Vivancos, A., Rovira, A., Tusquets, I., Albanell, J., Rodon, J., Tabernero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0531-8 · Cited by 519
Implementing Genome-Driven Oncology
Hyman, D. M., Taylor, B. S., & Baselga, J. (2017) · Cell · doi:10.1016/j.cell.2016.12.015 · Cited by 503
Subbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J., Takeda, M., Ohe, Y., Khan, S., Ohashi, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00541-1 · Cited by 449
Self-citationZill, O. A., Banks, K. C., Fairclough, S. R., Mortimer, S. A., Vowles, J. V., Mokhtari, R., Gandara, D. R., Mack, P. C., Odegaard, J. I., Nagy, R. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3837 · Cited by 391
Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
Marquart, J., Chen, E. Y., & Prasad, V. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1660 · Cited by 377
Wen, P. Y., Stein, A., van den Bent, M., De Greve, J., Wick, A., de Vos, F. Y. F. L., von Bubnoff, N., van Linde, M. E., Lai, A., Prager, G. W., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00578-7 · Cited by 369
Salama, A. K. S., Li, S., Macrae, E. R., Park, J.-I., Mitchell, E. P., Zwiebel, J. A., Chen, H. X., Gray, R. J., McShane, L. M., Rubinstein, L. V., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00762 · Cited by 308
Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03010 · Cited by 294
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Tong, J. T. W., Harris, P. W. R., Brimble, M. A., & Kavianinia, I. (2021) · Molecules · doi:10.3390/molecules26195847 · Cited by 287
Stockley, T. L., Oza, A. M., Berman, H. K., Leighl, N. B., Knox, J. J., Shepherd, F. A., Chen, E. X., Krzyzanowska, M. K., Dhani, N., Joshua, A. M., et al. (2016) · Genome Medicine · doi:10.1186/s13073-016-0364-2 · Cited by 276
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 266
Self-citationRoss, J. S., Wang, K., Gay, L., Otto, G. A., White, E., Iwanik, K., Palmer, G., Yelensky, R., Lipson, D. M., Chmielecki, J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.216 · Cited by 244
Clinical cancer genomic profiling
Chakravarty, D., & Solit, D. B. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00338-8 · Cited by 226
Self-citationOncoTree: A Cancer Classification System for Precision Oncology
Kundra, R., Zhang, H., Sheridan, R., Sirintrapun, S. J., Wang, A., Ochoa, A., Wilson, M., Gross, B. E., Sun, Y., Madupuri, R., et al. (2021) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00108 · Cited by 191
Self-citationAkhoundova, D., & Rubin, M. A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.011 · Cited by 182
Robbe, P., Popitsch, N., Knight, S. J. L., Antoniou, P., Becq, J., He, M., Kanapin, A., Samsonova, A., Vavoulis, D. V., Ross, M. T., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.241 · Cited by 178
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers
Stadler, Z. K., Maio, A., Chakravarty, D., Kemel, Y. M., Sheehan, M. R., Salo‐Mullen, E. E., Tkachuk, K. A., Fong, C. J., Nguyen, B., Erakky, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03661 · Cited by 175
Self-citationRose Brannon, A., Jayakumaran, G., Diosdado, M., Patel, J., Razumova, A., Hu, Y., Meng, F., Haque, M., Sadowska, J., Murphy, B. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24109-5 · Cited by 174
Self-citationBasket Trials in Oncology: A Trade-Off Between Complexity and Efficiency
Cunanan, K. M., Gönen, M., Shen, R., Hyman, D. M., Riely, G. J., Begg, C. B., & Iasonos, A. E. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9751 · Cited by 136
Huang, L., Fernandes, H., Zia, H. M., Tavassoli, P., Rennert, H., Pisapia, D. J., Imielinski, M. B., Sboner, A., Rubin, M. A., Kluk, M., et al. (2016) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocw148 · Cited by 116
Arora, K. S., Tran, T. N., Kemel, Y. M., Mehine, M. M., Liu, Y. L., Nandakumar, S., Smith, S. A., Brannon, A. R., Ostrovnaya, I., Stopsack, K. H., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0312 · Cited by 82
Self-citationPersonalized cancer therapy—leveraging a knowledge base for clinical decision-making
Dumbrava, E. I., & Meric‐Bernstam, F. (2017) · Molecular Case Studies · doi:10.1101/mcs.a001578 · Cited by 79
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes, D., Constantinescu, C. S., Vrancken, L., Rasche, L., Grégoire, C., Țigu, A. B., Gulei, D., Dima, D. M., Tănase, A., Einsele, H., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01296-2 · Cited by 74
Loong, H. H.-F., Shimizu, T., Prawira, A., Tan, A. C., Tran, B., Day, D., Tan, D. S. P., Ting, F. I. L., Chiu, J. W. Y., Hui, M. N., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101586 · Cited by 65
Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data
Patterson, S. E., Statz, C. M., Yin, T., & Mockus, S. M. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0073-y · Cited by 54
Seet, A. O. L., Tan, A. C., Tan, T. J., Ng, M. C. H., Tai, D. W.-M., Lam, J. Y. C., Tan, G. S., Gogna, A., Too, C. W., Tan, B. S., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00261 · Cited by 13
Cited by
Lung cancer in patients who have never smoked — an emerging disease
LoPiccolo, J., Gusev, A., Christiani, D. C., & Jänne, P. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00844-0 · Cited by 286
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
Self-citationLambourne, L., Mattioli, K., Santoso, C., Sheynkman, G., Inukai, S., Kaundal, B., Berenson, A., Spirohn-Fitzgerald, K., Bhattacharjee, A., Rothman, E., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.03.004 · Cited by 42
Estevam, G. O., Linossi, E., Rao, J., Macdonald, C. B., Ravikumar, A., Chrispens, K. M., Capra, J. A., Coyote-Maestas, W., Pimentel, H., Collisson, E. A., et al. (2025) · eLife · doi:10.7554/elife.101882 · Cited by 17
Kreimeyer, K., Canzoniero, J. V., Fatteh, M., Anagnostou, V., & Botsis, T. (2024) · Studies in Health Technology and Informatics · doi:10.3233/shti240575 · Cited by 8
Metadata
- Authors
- Suehnholz, S. P., Nissan, M. H., Zhang, H., Kundra, R., Nandakumar, S., Lu, C., Carrero, S., Dhaneshwar, A., Fernandez, N., Xu, B. W., Arcila, M. E., Zehir, A., Syed, A., Brannon, A. R., Rudolph, J. E., Paraiso, E., Sabbatini, P. J., Levine, R. L., Dogan, A., Gao, J., Ladanyi, M., Drilon, A., Berger, M. F., Solit, D. B., Schultz, N., & Chakravarty, D.
- Venue
- Cancer Discovery
- Published
- 2023-10-17
- Volume
- 14
- Issue
- 1
- Pages
- 49-65
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W4387728976
- Cited by
- 401
- References
- 50
- FWCI
- 40.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.